Skip to contentZ
Zentalis Pharmaceuticals, Inc.
Z
ZNTLZentalis Pharmaceuticals, Inc. ZNTL Q2 2020 · Zentalis Pharmaceuticals, Inc. · ThalerReleased Aug 13, 2020, before the open
10-Q filed Aug 13, 2020, 44 days after period end · 0001725160-20-000016
Q2 2020 · 10-Q
Revenue—
Net Income-$26.86M-$26.86MN/M vs Q2 2019N/M vs Q1 2020 EPS Diluted-$0.78-$0.78
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Zentalis Pharmaceuticals, Inc. · CIK 1725160 · Engraved from SEC EDGAR
N/M vs Q1 2020
Operating Income-$27,376,000N/M Operating Cash Flowderived-$22,033,000N/M Free Cash Flowderived-$22,058,000N/M Filing lag
ended Jun 30, 2020 · filed Aug 13, 2020 · 44 d after period end
+1.0% from the close of Aug 12, 2020 to the close of Aug 14, 2020, the first after the release.
before the open$32.56$32.90 Jul 20Aug 13Sep 14